Stockscreener 앱 받기
13.81
3.14%
0.42
시간 외 거래:
13.82
0.010
+0.07%
전일 마감가:
$13.39
열려 있는:
$13.36
하루 거래량:
114.73K
Relative Volume:
0.48
시가총액:
$188.11M
수익:
-
순이익/손실:
$-104.29M
주가수익비율:
-2.2891
EPS:
-6.0329
순현금흐름:
$-81.45M
1주 성능:
-7.93%
1개월 성능:
-9.74%
6개월 성능:
+121.95%
1년 성능:
+23.30%
1일 변동 폭
$13.18
$14.19
1주일 범위
$13.18
$15.40
52주 변동 폭
$5.062
$15.84
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
13.81 | 182.39M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-15 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2026-03-24 | 개시 | Guggenheim | Buy |
| 2025-11-07 | 개시 | Roth Capital | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IMUX|Immunic Inc|Price:13.390|Chg%:-0.890 - TradingKey
TradingKey - TradingKey
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic, Inc. Revenue Breakdown – NASDAQ:IMUX - TradingView
Immunic Inc. (IMUX) Edges Higher Amid Steady Trading: Key Levels to WatchBlock Trade Flow - dars.gov.et
Immunic lines up three July investor events in Boston and SF - Stock Titan
abrdn discloses 6.05% Immunic (IMUX) stake held for clients - Stock Titan
Immunic posts updated corporate presentation under Regulation FD - TradingView
Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans - Stock Titan
Immunic (IMUX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Immunic stock trades steadily as pipeline and Nasdaq listing shape investor focus - Ad-hoc-news.de
Immunic announces participation in July investor conferences - Proactive financial news
Immunic to Participate in Investor Conferences in July - Investing News Network
EQS-News: Immunic to Participate in Investor Conferences in Julyboerse.de - boerse.de
Immunic Names CEO Erik Lundgren to Board - The Globe and Mail
Form 4 Immunic Inc For: 7 July By Investing.com - Investing.com Nigeria
Immunic director granted options for 25,370 shares | IMUX Insider Trading - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay - Stock Titan
IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price - Stock Titan
Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80 - Stock Titan
Immunic, Inc. Files Form 8-K Announcing Key Company Details and Executive Update (June 29, 2026) - Minichart
Immunic (IMUX) CEO Erik Lundgren appointed to Board as Tamar Howson retires - Stock Titan
Immunic, Inc. Announces Board and Committee Changes - marketscreener.com
IMUXImmunic Inc Options - Finviz
IMUX Should I Buy - Intellectia AI
Form 4 Immunic Inc For: 29 June By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton awarded 50,740 stock options at $10.90 - Stock Titan
Immunic (IMUX) director receives 25,370 fully vested options - Stock Titan
Immunic (IMUX) director receives grant of 25,370 fully vested options - Stock Titan
Immunic (NASDAQ: IMUX) director receives 25,370 stock options grant - Stock Titan
Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips receives 25,370 fully vested stock options - Stock Titan
IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant - Stock Titan
IMMUNIC (IMUX) CFO awarded stock options for 120,000 common shares - Stock Titan
IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price - Stock Titan
[Form 4] IMMUNIC, INC. Insider Trading Activity - Stock Titan
Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting - Stock Titan
Immunic, Inc.(NasdaqCM: IMUX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Price to earnings forward of Immunic, Inc. – BOATS:IMUX - TradingView
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling - biocentury.com
IMUX News | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
IMUX Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Immunic, Inc. – MUN:10V - TradingView
Price to book forward of Immunic, Inc. – MUN:10V - TradingView
IMUX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Price to sales forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):